Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2127677

CCN(CC)c1ccc(-c2cn3cc(C(=N)NO)ccc3n2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.45
KDM4E B2RXH2 6/20 0.45
NPC1 O15118 5/20 0.45
RAB9A P51151 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
POLB P06746 2/20 0.45
GAA P10253 2/20 0.45
MEN1 O00255 1/20 0.43
HSP90AA1 P07900 1/20 0.43
KMT2A Q03164 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ALDH1A3 P47895 1/20 0.42
HPGDS O60760 4/20 0.41
GLA P06280 1/20 0.41
HPGD P15428 2/20 0.40
APP P05067 8/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2128030 0.91 KDM4E (0.47) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
Trifluoroacetic Acid SCHEMBL2128124 0.84 APP (0.58) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL2127590 0.81 ALDH1A1 (0.62) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
Bromide SCHEMBL2128134 0.80 ALDH1A1 (0.61) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
Trifluoroacetic Acid SCHEMBL2128917 0.79 APP (0.60) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL2128791 0.78 ALDH1A1 (0.65) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL2127100 0.76 NPC1 (0.60) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL2127679 0.76 ALDH1A1 (0.45) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL4951858 0.76 ALDH1A1 (0.53) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL2126828 0.75 ALDH1A3 (0.55) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
EP-2129375-B1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-04-25 EP disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
EP-2129375-A1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-12-09 EP disclosed
WO-2008104278-A1 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS NOS1, PTGIS, NOS2 ALDH1A1 1286/4885KDM4E 879/4885NPC1 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.